Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for enVVeno Medical Corporation (NVNO : NSDQ)
 
 • Company Description   
enVVeno Medical Corporation is a medical device company. It focuses in the treatment of venous disease. enVVeno Medical Corporation, formerly known as Hancock Jaffe Laboratories Inc., is based in IRVINE, CA.

Number of Employees: 24

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.16 Daily Weekly Monthly
20 Day Moving Average: 27,384 shares
Shares Outstanding: 9.47 (millions)
Market Capitalization: $39.39 (millions)
Beta: 1.37
52 Week High: $11.38
52 Week Low: $3.88
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -14.23% -3.40%
12 Week -8.37% 0.73%
Year To Date -36.87% -19.35%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
70 DOPPLER
-
IRVINE,CA 92618
USA
ph: 949-261-2900
fax: 949-261-2992
None http://www.hancockjaffe.com
 
 • General Corporate Information   
Officers
Robert Berman - Chief Executive Officer
Craig Glynn - Chief Financial Officer
Marc H. Glickman - Senior Vice President and Chief Medical Officer
Sanjay Shrivastava - Director
Matthew M. Jenusaitis - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED INSTRUMENTS
Sector: Medical
CUSIP: 29415J106
SIC: 3841
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/10/22
Share - Related Items
Shares Outstanding: 9.47
Most Recent Split Date: 11.00 (0.04:1)
Beta: 1.37
Market Capitalization: $39.39 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.53 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.77
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 2.08%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -37.30
12/31/21 - -33.67
09/30/21 - -31.97
ROA
03/31/22 - -35.76
12/31/21 - -32.36
09/30/21 - -30.33
Current Ratio
03/31/22 - 40.67
12/31/21 - 34.83
09/30/21 - 52.06
Quick Ratio
03/31/22 - 40.67
12/31/21 - 34.84
09/30/21 - 52.06
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 5.42
12/31/21 - 5.75
09/30/21 - 6.13
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©